Brokerage firm Jefferies Maintains its rating on Abbott Laboratories(NYSE:ABT). In a research note issued to the investors, the brokerage major Raises the price-target to $49.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Jul 14, 2016.
In a different note, On Jun 21, 2016, Edward Jones said it Upgrades its rating on Abbott Laboratories. The shares have been rated ‘Buy’ by the firm. On Jun 14, 2016, Jefferies said it Maintains its rating on Abbott Laboratories. In the research note, the firm Raises the price-target to $44.00 per share. The shares have been rated ‘Buy’ by the firm. On Apr 28, 2016, Piper Jaffray said it Downgrades its rating on Abbott Laboratories. In the research note, the firm Raises the price-target to $68.00 per share. The shares have been rated ‘Neutral’ by the firm.
Abbott Laboratories (ABT) shares turned negative on Mondays trading session with the shares closing down -0.01 points or -0.02% at a volume of 75,24,201. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $42.229. The peak price level was also seen at $42.229 while the days lowest was $41.81. Finally the shares closed at $42.09. The 52-week high of the shares is $51.74 while the 52-week low is $36. According to the latest information available, the market cap of the company is $61,837 M.
Abbott Laboratories(ABT) last announced its earnings results on Apr 20, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $4.88B. Analysts had an estimated revenue of $4.77B. Earnings per share were $0.41. Analysts had estimated an EPS of $0.39.
Several Insider Transactions has been reported to the SEC. On Jun 30, 2016, Hubert L Allen (Executive Vice President) sold 3,400 shares at $37.14 per share price.Also, On Jun 17, 2016, Jared Watkin (Senior Vice President) sold 552 shares at $37.63 per share price.On Jun 3, 2016, Brian B Yoor (Senior Vice President and CFO) sold 565 shares at $39.49 per share price, according to the Form-4 filing with the securities and exchange commission.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.